A Prospective, Randomized Double-Blind Phase III Trial Of Aprepitant vs. Placebo Plus Oral Ondansetron And Dexamethasone For The Prevention Of Nausea And Vomiting (N/V) Associated With Highly Emetogenic Preparative Regimens Prior To Hematopoietic Stem Cell Transplantation (HSCT)  by Stiff, P.J. et al.
S156 CIBMTR Best Abstract Awards for Clinical Researchfactors such as age, degree of HLA-match, and conditioning inten-
sity (p5 0.05). In this large set, frequency of CD4+CD25hiFOXP3+
Tregs at onset of GVHD correlates with GVHD severity, eventual
maximumGVHDgrade andNRM. Treg frequency thus has impor-
tant diagnostic and prognostic value as a biomarker for acute
GVHD.6
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Delayed N/V is often a major toxicity in patients undergoing
ablative preparative regimens prior to HSCT. Aprepitant (APR),
an NK-1 antagonist is effective in preventing delayed N/V with
moderate and highly emetogenic standard dose chemotherapy and
thus may be of value in the transplant setting. However APR inter-
acts with cytochrome P450 involved in the bioactivation of high
dose cyclophosphamide, and may interfere with etoposide pharma-
cokinetics; thus may impact regimen related toxicity (RRT) and sur-
vival post transplant. While several small Phase II studies have
suggested the benefit of APR in HSCT, no prospective comparisons
have been reported.We performed a randomized (1:1) blinded Phase
III trial to determine the safety and efficacy of APR for N/V due to
ablative preparative regimens. Patients received either placebo
(PBO) or oral APR 125 mg PO day 1 then 80 mg daily for all days
of the preparative regimen and for 3 days after it ended, in addition
to oral ondansetron 8 mg PO q 8hrs + IV dexamethasone (DEX)
daily during and for 1 day after the preparative regimen. Due to
a known drug interaction between APR and dexamethasone, blinded
DEXdoses were used (10 mg -placebo; 7.5 mg – APR). Patients were
stratified based on gender; those with heavy ETOH use were ex-cluded. Clinical evaluations were performed daily with the primary
endpoint being a CR, defined as: no emesis and no or mild nausea
[less than grade (gr) 3 using CTC 2.0 criteria]. Other endpoints in-
cluded; major response (MR): 1 episode of emesis or moderate nau-
sea; minor response (mR): 2–4 episodes of emesis; and failure (F):.4
episodes of emesis. Major efficacy (ME)5CR +MR. Nausea was
measured on a 100 mm visual analog scale (VAS) with 05 no nausea.
Safety analyses performed included grade 3-5 toxicities, time to en-
graftment, PFS andOS. The 181 randomized patients were balanced
with respect to age, weight, donor source and h/o N/V with prior
chemotherapy. Patients received one of 5 ablative prep regimens:
CY/TBI/VP16 (36), CY/TBI (79), IV BU/CY (19), PO BU/CY
(34), and BCV(16). Two pts never proceeded to transplant so only
179 pts are eligible for analysis. Efficacy: see Table. Days to engraft-
ment; grade 3-5 RRT, PFS and OS were identical between the two
groups.
Conclusions: When used up to 10 days with ablative HSCT regi-
mens, aprepitant significantly improved N/V with a major impact
on emesis rates. It appears safe for this indication with no impact
on WBC and PLT engraftment or PFS/OS.
Ondansetron/dexamethasone 1/- Aprepitant for BMT regi-
men related N/V: Results
Aprepitant Placebo p value% ptts with no emesis during
study period73.3 22.5 \0.001% pts with CR: no emesis1\ gr 3
nausea during entire period48.9 14.6 \0.001% of days no emesis and
\ gr 3 nasuea, all pts81.9 65.8 \0.001Ave VAS scores 16.5 16.9 0.892
Composite MR 16.0 16.9 0.011
Composite mR 2.0 10.3 \0.001
Composite F 0.1 2.2 0.001
Composite ME 97.9 87.4 \0.001
